56 related articles for article (PubMed ID: 16761015)
1. The role of the bax gene polymorphism G(-248)A in chronic lymphocytic leukemia.
Fegan C; Starczynski J; Pratt G; Pepper C
Leukemia; 2006 Aug; 20(8):1460-1. PubMed ID: 16761015
[No Abstract] [Full Text] [Related]
2. Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survival.
Nückel H; Frey UH; Sellmann L; Bau M; Dürig J; Dührsen U; Siffert W
Leukemia; 2006 Apr; 20(4):724. PubMed ID: 16453002
[No Abstract] [Full Text] [Related]
3. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia.
Skogsberg S; Tobin G; Kröber A; Kienle D; Thunberg U; Aleskog A; Karlsson K; Laurell A; Merup M; Vilpo J; Sundström C; Roos G; Jernberg-Wiklund H; Döhner H; Nilsson K; Stilgenbauer S; Rosenquist R
Leukemia; 2006 Jan; 20(1):77-81. PubMed ID: 16307023
[TBL] [Abstract][Full Text] [Related]
4. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
Starczynski J; Pepper C; Pratt G; Hooper L; Thomas A; Milligan D; Bentley P; Fegan C
J Clin Oncol; 2005 Mar; 23(7):1514-21. PubMed ID: 15735127
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.
Thomas A; El Rouby S; Reed JC; Krajewski S; Silber R; Potmesil M; Newcomb EW
Oncogene; 1996 Mar; 12(5):1055-62. PubMed ID: 8649796
[TBL] [Abstract][Full Text] [Related]
6. Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells.
Bogner C; Sandherr M; Perker M; Weick K; Ringshausen I; Peschel C; Decker T
Ann Hematol; 2006 Jul; 85(7):458-62. PubMed ID: 16538501
[TBL] [Abstract][Full Text] [Related]
7. G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression.
Moshynska O; Moshynskyy I; Misra V; Saxena A
Oncogene; 2005 Mar; 24(12):2042-9. PubMed ID: 15688029
[TBL] [Abstract][Full Text] [Related]
8. Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease.
Molica S; Dattilo A; Giulino C; Levato D; Levato L
Haematologica; 1998 Dec; 83(12):1122-4. PubMed ID: 9949631
[TBL] [Abstract][Full Text] [Related]
9. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
Scamardella F; Maconi M; Albertazzi L; Gamberi B; Gugliotta L; Brini M
Lab Hematol; 2006; 12(4):187-92. PubMed ID: 17118768
[TBL] [Abstract][Full Text] [Related]
10. The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.
Kaderi MA; Norberg M; Murray F; Merup M; Sundström C; Roos G; Aleskog A; Karlsson K; Axelsson T; Tobin G; Rosenquist R
Leukemia; 2008 Feb; 22(2):339-43. PubMed ID: 18046447
[TBL] [Abstract][Full Text] [Related]
11. P2X7 polymorphism and chronic lymphocytic leukaemia.
Mitsiades CS; Mitsiades N
Lancet; 2003 Apr; 361(9367):1478; author reply 1478-9. PubMed ID: 12727428
[No Abstract] [Full Text] [Related]
12. BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia.
Anderson MA; Huang DC; Roberts AW
Leuk Lymphoma; 2013 May; 54(5):909-11. PubMed ID: 23339446
[No Abstract] [Full Text] [Related]
13. Prognostic assessment of BCL2-938C>A polymorphism in chronic lymphocytic leukemia.
Rossi D; Rasi S; Capello D; Gaidano G
Blood; 2008 Jan; 111(1):466-8. PubMed ID: 18156504
[No Abstract] [Full Text] [Related]
14. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
Iglesias-Serret D; Coll-Mulet L; Santidrián AF; Navarro-Sabaté A; Domingo A; Pons G; Gil J
J Natl Cancer Inst; 2005 Jul; 97(14):1090-1; author reply 1093-5. PubMed ID: 16030310
[No Abstract] [Full Text] [Related]
15. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia.
Riemann K; Becker L; Struwe H; Nückel H; Dührsen U; Alakus H; Winde G; Neuhäuser M; Rübben H; Schmitz KJ; Wohlschlaeger J; Schmid KW; Siffert W
Pharmacogenet Genomics; 2006 Nov; 16(11):783-8. PubMed ID: 17047486
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.
Saxena A; Viswanathan S; Moshynska O; Tandon P; Sankaran K; Sheridan DP
Am J Hematol; 2004 Jan; 75(1):22-33. PubMed ID: 14695629
[TBL] [Abstract][Full Text] [Related]
17. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
18. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
Dicker F; Rauhut S; Kohlmann A; Kern W; Schoch C; Haferlach T; Schnittger S
J Natl Cancer Inst; 2005 Jul; 97(14):1092-3; author reply 1093-5. PubMed ID: 16030312
[No Abstract] [Full Text] [Related]
19. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome.
Nückel H; Frey UH; Dürig J; Dührsen U; Siffert W
Eur J Haematol; 2004 Apr; 72(4):259-63. PubMed ID: 15089763
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells.
Sanz L; Garcia-Marco JA; Casanova B; de La Fuente MT; García-Gila M; Garcia-Pardo A; Silva A
Biochem Biophys Res Commun; 2004 Mar; 315(3):562-7. PubMed ID: 14975737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
